Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Akoya Biosciences's share price for the quarter that ended in Mar. 2024 was $4.69. Akoya Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 49.34 Mil. Therefore, Akoya Biosciences's market cap for the quarter that ended in Mar. 2024 was $231.41 Mil.
Akoya Biosciences's quarterly market cap
increased
from Sep. 2023 ($228.14 Mil) to Dec. 2023 ($239.69 Mil) but then
declined
from Dec. 2023 ($239.69 Mil) to Mar. 2024 ($231.41 Mil).
Akoya Biosciences's annual market cap
declined
from Dec. 2021 ($572.96 Mil) to Dec. 2022 ($366.42 Mil) and
declined
from Dec. 2022 ($366.42 Mil) to Dec. 2023 ($239.69 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Akoya Biosciences's Enterprise Value for Today is $153.99 Mil.
Akoya Biosciences Market Cap Historical Data
The historical data trend for Akoya Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akoya Biosciences's Market Cap
For the Medical Instruments & Supplies subindustry, Akoya Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akoya Biosciences's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Akoya Biosciences's Market Cap falls into.
Akoya Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Akoya Biosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akoya Biosciences (NAS:AKYA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Akoya Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Akoya Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Akoya Biosciences (Akoya Biosciences) Business Description
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKYA has been successfully added to your 